Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Elacestrant, a non-steroidal small molecule, is an estrogen receptor (ER) antagonist. Erastratran binds to estrogen receptor α (ERα) and acts as a selective estrogen receptor degra···【more】
Article source：Captain MedicineRelease date：2024-11-13Recommended：262
Balversa is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) used to treat cancer. It is the first personalized treatment drug for susceptible FGFR gene mutat···【more】
Article source：Captain MedicineRelease date：2024-11-13Recommended：266
Retinitis due to cytomegalovirus is indeed a serious eye infection that mainly affects people with weakened immune systems, such as AIDS patients. The virus can continue to damage ···【more】
Article source：Captain MedicineRelease date：2024-11-12Recommended：284
1. Targeted therapySpecific inhibitionAs a tyrosine kinase inhibitor, balversa specifically targets the FGFR (fibroblast growth factor receptor) signaling pathway. FGFR is abnormal···【more】
Article source：Captain MedicineRelease date：2024-11-12Recommended：286
Capmatinib has shown significant efficacy in the treatment of non-small cell lung cancer (NSCLC) with mutations in MET exon 14, and its side effects are relatively manageable. The ···【more】
Article source：Captain MedicineRelease date：2024-11-11Recommended：344
The neoadjuvant regimen of Pralsetinib is primarily based on its significant efficacy in RET fusion-positive tumors. Neoadjuvant therapy refers to adjuvant therapy given prior to s···【more】
Article source：Captain MedicineRelease date：2024-11-11Recommended：238
Fidaxomicinis a macrolide antibiotic developed by Optimer, which is mainly used for the treatment of refractory Clostridium infection, with a novel mechanism of action and signific···【more】
Article source：Captain MedicineRelease date：2024-08-30Recommended：236
Fidaxomicinis a macrolide antibiotic developed by Optimer, which is mainly used for the treatment of refractory Clostridium infection and exerts efficacy by inhibiting bacterial RN···【more】
Article source：Captain MedicineRelease date：2024-08-30Recommended：270
Stiripentol significantly reduces generalized seizures by enhancing GABAergic nerve conduction. Since its approval by the FDA, it has become an important drug to help patients cont···【more】
Article source：Captain MedicineRelease date：2024-08-29Recommended：275
Fidaxomicin is an antibiotic carefully developed by Optimer to treat refractory Clostridium infections and has demonstrated excellent efficacy and safety through a unique mechanism···【more】
Article source：Captain MedicineRelease date：2024-08-29Recommended：268
Fidaxomicinis an innovative macrolide antibiotic that has demonstrated its potent therapeutic ability against refractory Clostridium infections by blocking bacterial RNA polymerase···【more】
Article source：Captain MedicineRelease date：2024-08-29Recommended：285
Fidaxomicinis a new star of macrolide antibiotics developed by Optimer, which has a specific effect on refractory Clostridium infection and has demonstrated excellent therapeutic p···【more】
Article source：Captain MedicineRelease date：2024-08-29Recommended：261
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1692025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4082024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1632025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1832025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1632025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1982025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1762025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1712025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
